← All trials
NCT05126628
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 6, 2021
- Primary completion
- Mar 16, 2021
- Completion date
- Apr 15, 2021
- First posted
- Nov 19, 2021
- Last posted
- Nov 19, 2021
- Enrollment
- 133
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Corpometria InstituteLead sponsor
- Hospital Arcanjo Sao Miguel, Gramado, BrazilCollaborator
- Hospital da Brigada Militar de Porto Alegre, Porto Alegre, BrazilCollaborator
- Hospital Unimed Chapeco, Chapeco, BrazilCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.